Skip to content

Serum alpha 2 - rich in leucine glycoprotein 1 for chronic kidney disease (CKD) predictive value of cardiovascular events

Serum alpha 2 - rich in leucine glycoprotein 1 for chronic kidney disease (CKD) predictive value of cardiovascular events

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059037
Enrollment
Unknown
Registered
2022-04-23
Start date
2022-04-12
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

CKD stage 3-5:None
Healthy control:None

Sponsors

Huai 'an Hospital affiliated to Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria for CKD: the definition and diagnostic criteria of CKD refer to the K/DOQI guidelines issued by the national kidney foundation of the United States, which are defined as long-term renal dysfunction and structural abnormalities caused by various causes, lasting for 3 months or more, and the diagnostic criteria are glomerular filtration rate less than 60ml/min.

Exclusion criteria

Exclusion criteria: 1. Patients with underlying heart diseases: patients with cardiac function of grade III-IV and significantly limited physical activity, severe heart failure, acute myocardial infarction, congenital hypertrophic cardiomyopathy, valvular heart disease, rheumatic heart disease, hyperthyroidism heart disease, pulmonary heart disease, post-bypass surgery, myocarditis, pericardial disease, etc.; Or a recent acute cardiovascular event; 2. Recent complicated severe infection; 3. Complicated with severe hepatobiliary disease, active or wasting disease (such as malignant tumor, severe tuberculosis); 4. Patients with primary parathyroid disease and parathyroidectomy cannot be excluded if thyroid disease has an impact on heart structure and function; 5. Patients who have used glucocorticoids or immunosuppressive therapy and ACEI/ARB drugs in the last six months.

Design outcomes

Primary

MeasureTime frame
Serum alpha 2 - rich in leucine glycoprotein 1;

Countries

China

Contacts

Public ContactDonghui Zheng

Huai 'an Hospital affiliated to Xuzhou Medical University

1042693665@qq.com+86 15700986210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026